Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
Metformin, the most widely prescribed drug therapy for type 2 diabetes, has pleiotropic benefits, in addition to its capacity to lower elevated blood glucose levels, including mitigation of cardiovascular risk. The mechanisms underlying the latter remain unclear. Mechanistic studies have, hitherto,...
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
MDPI AG
2020-11-01
|
| coleção: | Pharmaceuticals |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1424-8247/13/11/410 |
| _version_ | 1827701708881395712 |
|---|---|
| author | Malcolm J. Borg Christopher K. Rayner Karen L. Jones Michael Horowitz Cong Xie Tongzhi Wu |
| author_facet | Malcolm J. Borg Christopher K. Rayner Karen L. Jones Michael Horowitz Cong Xie Tongzhi Wu |
| author_sort | Malcolm J. Borg |
| collection | DOAJ |
| description | Metformin, the most widely prescribed drug therapy for type 2 diabetes, has pleiotropic benefits, in addition to its capacity to lower elevated blood glucose levels, including mitigation of cardiovascular risk. The mechanisms underlying the latter remain unclear. Mechanistic studies have, hitherto, focused on the direct effects of metformin on the heart and vasculature. It is now appreciated that effects in the gastrointestinal tract are important to glucose-lowering by metformin. Gastrointestinal actions of metformin also have major implications for cardiovascular function. This review summarizes the gastrointestinal mechanisms underlying the action of metformin and their potential relevance to cardiovascular benefits. |
| first_indexed | 2024-03-10T14:40:10Z |
| format | Article |
| id | doaj.art-a8daeecc10fb48a6bbfa2297e4eae7e7 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T14:40:10Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-a8daeecc10fb48a6bbfa2297e4eae7e72023-11-20T21:52:52ZengMDPI AGPharmaceuticals1424-82472020-11-01131141010.3390/ph13110410Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of MetforminMalcolm J. Borg0Christopher K. Rayner1Karen L. Jones2Michael Horowitz3Cong Xie4Tongzhi Wu5Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, AustraliaAdelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, AustraliaAdelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, AustraliaAdelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, AustraliaAdelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, AustraliaAdelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide 5000, AustraliaMetformin, the most widely prescribed drug therapy for type 2 diabetes, has pleiotropic benefits, in addition to its capacity to lower elevated blood glucose levels, including mitigation of cardiovascular risk. The mechanisms underlying the latter remain unclear. Mechanistic studies have, hitherto, focused on the direct effects of metformin on the heart and vasculature. It is now appreciated that effects in the gastrointestinal tract are important to glucose-lowering by metformin. Gastrointestinal actions of metformin also have major implications for cardiovascular function. This review summarizes the gastrointestinal mechanisms underlying the action of metformin and their potential relevance to cardiovascular benefits.https://www.mdpi.com/1424-8247/13/11/410metformincardiovasculargastrointestinalmechanismsbile acidsgut microbiota |
| spellingShingle | Malcolm J. Borg Christopher K. Rayner Karen L. Jones Michael Horowitz Cong Xie Tongzhi Wu Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin Pharmaceuticals metformin cardiovascular gastrointestinal mechanisms bile acids gut microbiota |
| title | Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin |
| title_full | Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin |
| title_fullStr | Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin |
| title_full_unstemmed | Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin |
| title_short | Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin |
| title_sort | gastrointestinal mechanisms underlying the cardiovascular effect of metformin |
| topic | metformin cardiovascular gastrointestinal mechanisms bile acids gut microbiota |
| url | https://www.mdpi.com/1424-8247/13/11/410 |
| work_keys_str_mv | AT malcolmjborg gastrointestinalmechanismsunderlyingthecardiovasculareffectofmetformin AT christopherkrayner gastrointestinalmechanismsunderlyingthecardiovasculareffectofmetformin AT karenljones gastrointestinalmechanismsunderlyingthecardiovasculareffectofmetformin AT michaelhorowitz gastrointestinalmechanismsunderlyingthecardiovasculareffectofmetformin AT congxie gastrointestinalmechanismsunderlyingthecardiovasculareffectofmetformin AT tongzhiwu gastrointestinalmechanismsunderlyingthecardiovasculareffectofmetformin |